Wang Z K, Zhang J H, Chen X S, Liu Q F, Wang J B, Wu R Y, Zhang Y, Wang K, Qu Y, Huang X D, Xiao J P, Gao L, Xu G Z, Yi J L, Luo J W
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhonghua Zhong Liu Za Zhi. 2022 Feb 23;44(2):185-191. doi: 10.3760/cma.j.cn112152-20200509-00433.
To analyze the efficacy of sinonasal adenoid cystic carcinoma (ACC) with perineural invasion (PNI), and explore the prognostic value of PNI on sinonasal adenoid cystic carcinoma. The clinical data of 105 patients with sinonasal ACC admitted to Cancer Hospital, Chinese Academy of Medical Sciences from January 2000 to December 2016 were retrospectively reviewed. All patients were restaged according to American Joint Committee on Cancer 8th edition. Follow-up visits were conducted to obtain information of treatment failure and survival outcome. The Log rank test was used for univariate analysis of prognostic factors, and Cox regression model was used for multivariate prognostic analysis. The maxillary sinus (=59) was the most common primary site, followed by the nasal cavity (=38). There were 93 patients with stage Ⅲ-Ⅳ. The treatment modalities included surgery alone (=14), radiotherapy alone (=13), preoperative radiotherapy plus surgery (=10), and surgery plus postoperative radiotherapy (=68). The median follow-up time was 91.8 months, the 5-year local control (LC), distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival (OS) rates were 72.6%, 73.0%, 52.9% and 78.0%, respectively. There were 33 patients (31.4%) with PNI-positive. The 5-year DMFS, PFS, and OS rates of PNI-positive group were 53.7%, 29.4% and 56.5%, respectively, which were significantly inferior to those of PNI-negative group (80.8%, 63.0% and 86.8%, respectively, <0.05), while there was no significant difference in the 5-year LC rate between both groups (64.5% vs 76.5%, =0.273). The multivariate Cox regression analysis showed PNI was one of the poor prognostic factors of DMFS (=3.514, 95% 1.557-7.932), PFS (=2.562, 95% 1.349-4.866) and OS (=2.605, 95% 1.169-5.806). Among patients with PNI-positive, the 5-year LC, PFS and OS rates of patients received surgery combined with radiotherapy were 84.9%, 41.3% and 72.7%, respectively, which were significantly higher than 23.3%, 10.0% and 26.7% of patients receiving surgery or radiotherapy alone (<0.05). The presence of PNI increases the risk of distant metastasis in patients with sinonasal ACC. Compared with patients with PNI-negative, the prognosis of patients with PNI-positive is relatively poor, and surgery combined with radiotherapy for PNI-positive sinonasal ACC results in good clinical outcomes.
分析鼻窦腺样囊性癌(ACC)伴神经侵犯(PNI)的疗效,并探讨PNI对鼻窦腺样囊性癌的预后价值。回顾性分析2000年1月至2016年12月在中国医学科学院肿瘤医院收治的105例鼻窦ACC患者的临床资料。所有患者均根据美国癌症联合委员会第8版进行重新分期。进行随访以获取治疗失败和生存结果的信息。采用Log rank检验对预后因素进行单因素分析,采用Cox回归模型进行多因素预后分析。上颌窦(=59)是最常见的原发部位,其次是鼻腔(=38)。有93例Ⅲ-Ⅳ期患者。治疗方式包括单纯手术(=14)、单纯放疗(=13)、术前放疗加手术(=10)和手术加术后放疗(=68)。中位随访时间为91.8个月,5年局部控制(LC)、无远处转移生存(DMFS)、无进展生存(PFS)和总生存(OS)率分别为72.6%、73.0%、52.9%和78.0%。有33例(31.4%)患者PNI阳性。PNI阳性组的5年DMFS、PFS和OS率分别为53.7%、29.4%和56.5%,显著低于PNI阴性组(分别为80.8%、63.0%和86.8%,<0.05),而两组的5年LC率无显著差异(64.5%对76.5%,=0.273)。多因素Cox回归分析显示PNI是DMFS(=3.514,95% 1.557 - 7.932)、PFS(=2.562,95% 1.349 - 4.866)和OS(=2.605,95% 1.169 - 5.806)的不良预后因素之一。在PNI阳性患者中,接受手术联合放疗的患者的5年LC、PFS和OS率分别为84.9%、41.3%和72.7%,显著高于单纯接受手术或放疗的患者的23.3%、10.0%和26.7%(<0.05)。PNI的存在增加了鼻窦ACC患者远处转移的风险。与PNI阴性患者相比,PNI阳性患者的预后相对较差,PNI阳性的鼻窦ACC患者手术联合放疗可取得良好的临床疗效。